Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Dosimetry of 68Ga-OncoACP3 Imaging in Prostate Cancer
NCT07600554Phase 1Completed
- Sponsor
- Philogen
- Start
- May 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 68Ga-Onco-ACP3 in prostate cancer (PCa) (2 cohorts), sponsored by Philogen. Primary endpoints: Adverse events and Serious Adverse Events at 7 days and Effective dose equivalent and absorbed doses at Day 1. Started May 2026; status: completed.
02
Drugs
68Ga-Onco-ACP3
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07600554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07600554.